Background Stroke thrombolysis with alteplase is currently recommended 0-4•5 h after stroke onset. We aimed to determine whether perfusion imaging can identify patients with salvageable brain tissue with symptoms 4•5 h or more from stroke onset or with symptoms on waking who might benefit from thrombolysis.Methods In this systematic review and meta-analysis of individual patient data, we searched PubMed for randomised trials published in English between Jan 1, 2006, and March 1, 2019. We also reviewed the reference list of a previous systematic review of thrombolysis and searched ClinicalTrials.gov for interventional studies of ischaemic stroke. Studies of alteplase versus placebo in patients (aged ≥18 years) with ischaemic stroke treated more than 4•5 h after onset, or with wake-up stroke, who were imaged with perfusion-diffusion MRI or CT perfusion were eligible for inclusion. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score 0-1) at 3 months, adjusted for baseline age and clinical severity. Safety outcomes were death and symptomatic intracerebral haemorrhage. We calculated odds ratios, adjusted for baseline age and National Institutes of Health Stroke Scale score, using mixed-effects logistic regression models. This study is registered with PROSPERO, number CRD42019128036. FindingsWe identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome at 3 months (adjusted odds ratio [OR] 1•86, 95% CI 1•15-2•99, p=0•011). Symptomatic intracerebral haemorrhage was more common in the alteplase group than the placebo group (ten [5%] of 213 patients vs one [<1%] of 201 patients in the placebo group; adjusted OR 9•7, 95% CI 1•23-76•55, p=0•031). 29 (14%) of 213 patients in the alteplase group and 18 (9%) of 201 patients in the placebo group died (adjusted OR 1•55, 0•81-2•96, p=0•66).Interpretation Patients with ischaemic stroke 4•5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo. The rate of symptomatic intracerebral haemorrhage was higher with alteplase, but this increase did not negate the overall net benefit of thrombolysis.
Abstract. We determine the number of ordered factorisations of an arbitrary permutation on n symbols into transpositions such that the factorisations have minimal length and such that the factors generate the full symmetric group on n symbols. Such factorisations of the identity permutation have been considered by Crescimanno and Taylor in connection with a class of topologically distinct holomorphic maps on the sphere. As with Macdonald's construction for symmetric functions that multiply as the classes of the class algebra, essential use is made of Lagrange inversion.
Double Hurwitz numbers count branched covers of CP 1 with fixed branch points, with simple branching required over all but two points 0 and ∞, and the branching over 0 and ∞ specified by partitions of the degree (with m and n parts, respectively). Single Hurwitz numbers (or more usually, Hurwitz numbers) have a rich structure, explored by many authors in fields as diverse as algebraic geometry, symplectic geometry, combinatorics, representation theory, and mathematical physics. The remarkable ELSV formula relates single Hurwitz numbers to intersection theory on the moduli space of curves. This connection has led to many consequences, including Okounkov and Pandharipande's proof of Witten's conjecture.In this paper, we determine the structure of double Hurwitz numbers using techniques from geometry, algebra, and representation theory. Our motivation is geometric: we give evidence that double Hurwitz numbers are top intersections on a moduli space of curves with a line bundle (a universal Picard variety). In particular, we prove a piecewise-polynomiality result analogous to that implied by the ELSV formula. In the case m = 1 (complete branching over one point) and n is arbitrary, we conjecture an ELSV-type formula, and show it to be true in ଁ I.P.G. and D.M.J. 44 I.P. Goulden et al. / Advances in Mathematics 198 (2005) 43 -92 genus 0 and 1. The corresponding Witten-type correlation function has a richer structure than that for single Hurwitz numbers, and we show that it satisfies many geometric properties, such as the string and dilaton equations, and an Itzykson-Zuber-style genus expansion ansatz. We give a symmetric function description of the double Hurwitz generating series, which leads to explicit formulae for double Hurwitz numbers with given m and n, as a function of genus. In the case where m is fixed but not necessarily 1, we prove a topological recursion on the corresponding generating series, which leads to closed-form expressions for double Hurwitz numbers and an analogue of the Goulden-Jackson polynomiality conjecture (an early conjectural variant of the ELSV formula). In a later paper (Faber's intersection number conjecture and genus 0 double Hurwitz numbers, 2005, in preparation), the formulae in genus 0 will be shown to be equivalent to the formulae for "top intersections" on the moduli space of smooth curves M g . For example, three formulae we give there will imply Faber's intersection number conjecture (in: Moduli of Curves and Abelian Varieties, Aspects of Mathematics, vol. E33, Vieweg, Braunschweig, 1999, pp. 109-129) in arbitrary genus with up to three points.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.